Insmed stock kpis
Want to see INSM full AI Analyst Report?
Revenue by Segment
Breaks revenue into business lines—primarily product sales (e.g., ARIKAYCE), licensing, and milestone or collaboration income—to show whether earnings are driven by repeatable commercial performance or one‑time events. For Insmed, a high share of product revenue points to commercial traction and more predictable cash flow, while reliance on milestone/license payments raises volatility. Tracking the mix over time helps assess durability of growth, concentration risk, and the company’s path to sustainable profitability.
BRINSUPRI has become the company’s clear growth engine, delivering a historic launch that materially reweights revenue and allowed management to raise FY guidance and peak sales assumptions; improved gross‑to‑net and rapid prescriber/patient uptake strengthen near‑term margins. ARIKAYCE remains a steady, modest cash generator absent label expansion. Key risks for investors: sustaining ~7,000 new starts/quarter, rising GTN over time, higher R&D/SG&A and a $50M AstraZeneca milestone in H2—offset by a ~$1.2B cash runway and a path to 2027 cash‑flow positivity.
INSM Revenue by Segment
| Date | ARIKAYCE | BRINSUPRI |
|---|---|---|
| Sep 30, 2026 | $124.38M | $400.05M |
| Jun 30, 2026 | $116.32M | $309.17M |
| Mar 31, 2026 | $98.10M | $207.90M |
| Dec 31, 2025 | $119.20M | $144.60M |
| Sep 30, 2025 | $114.30M | $28.10M |

